New York Demo Day June 29th; San Francisco early applications due June 30th

Learn more about investing in Kalia Health

Our team will get back to you soon to follow up on your inquiry.
Lead Rounds?
Denali Dahl, CEO
“Preeclampsia is the second leading cause of maternal mortality worldwide. By providing a home based diagnostic test to detect symptoms earlier, we can reduce these numbers and save more lives.”
21.3 million pregnancies are affected by preeclampsia globally every year.

Preeclampsia, a potentially fatal pregnancy condition characterized by high blood pressure and organ damage, is the second leading cause of maternal mortality worldwide, despite the condition being straightforward to treat when detected early. The current diagnosis of preeclampsia using blood pressure and proteinuria is inaccurate and requires routine clinical visits, making it inaccessible to many. Furthermore, symptoms are subtle so birthing people are often unaware of the developing complications unless they attend regular prenatal care checkups.

Kalia Health is dedicated to improving maternal health through engineering a safe, affordable, and accessible home-based early detection test for preeclampsia (PE). The lateral flow device identifies urinary biomarkers specific to PE for a more real-time diagnosis. This test will increase the number of birthing people that self-detect and seek prenatal care for PE through home diagnosis, education, and empowerment.